These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 38517084)
1. Randomized Controlled Trial of Intravenous Ferric Carboxymaltose vs Oral Iron to Treat Iron Deficiency Anemia After Variceal Bleed in Patients With Cirrhosis. Tabish M; Agarwal S; Gopi S; Rana R; Ahmed S; Gunjan D; Sharma S; Saraya A Am J Gastroenterol; 2024 Oct; 119(10):2061-2069. PubMed ID: 38517084 [TBL] [Abstract][Full Text] [Related]
2. Improved Hemoglobin Response with Ferric Carboxymaltose in Patients with Gastrointestinal-Related Iron-Deficiency Anemia Versus Oral Iron. Lichtenstein GR; Onken JE Dig Dis Sci; 2018 Nov; 63(11):3009-3019. PubMed ID: 30056562 [TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of intravenous ferric carboxymaltose in Japanese patients with iron-deficiency anemia caused by digestive diseases: an open-label, single-arm study. Ikuta K; Ito H; Takahashi K; Masaki S; Terauchi M; Suzuki Y Int J Hematol; 2019 Jan; 109(1):50-58. PubMed ID: 30194568 [TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy and safety of intravenous ferric carboxymaltose and iron sucrose for iron deficiency anemia in obstetric and gynecologic patients: A systematic review and meta-analysis. Shin HW; Go DY; Lee SW; Choi YJ; Ko EJ; You HS; Jang YK Medicine (Baltimore); 2021 May; 100(20):e24571. PubMed ID: 34011020 [TBL] [Abstract][Full Text] [Related]
5. Long-Term Effectiveness of Oral Ferric Maltol vs Intravenous Ferric Carboxymaltose for the Treatment of Iron-Deficiency Anemia in Patients With Inflammatory Bowel Disease: A Randomized Controlled Noninferiority Trial. Howaldt S; Domènech E; Martinez N; Schmidt C; Bokemeyer B Inflamm Bowel Dis; 2022 Mar; 28(3):373-384. PubMed ID: 33988236 [TBL] [Abstract][Full Text] [Related]
6. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Macdougall IC; Bock AH; Carrera F; Eckardt KU; Gaillard C; Van Wyck D; Roubert B; Nolen JG; Roger SD; Nephrol Dial Transplant; 2014 Nov; 29(11):2075-84. PubMed ID: 24891437 [TBL] [Abstract][Full Text] [Related]
7. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Van Wyck DB; Mangione A; Morrison J; Hadley PE; Jehle JA; Goodnough LT Transfusion; 2009 Dec; 49(12):2719-28. PubMed ID: 19682342 [TBL] [Abstract][Full Text] [Related]
8. Pediatric Crohn's disease, iron deficiency anemia and intravenous iron treatment: a follow-up study. Valério de Azevedo S; Maltez C; Lopes AI Scand J Gastroenterol; 2017 Jan; 52(1):29-33. PubMed ID: 27576956 [TBL] [Abstract][Full Text] [Related]
9. A Prospective Randomised Controlled Trial of a Single Intravenous Infusion of Ferric Carboxymaltose vs Single Intravenous Iron Polymaltose or Daily Oral Ferrous Sulphate in the Treatment of Iron Deficiency Anaemia in Pregnancy. Khalafallah AA; Hyppa A; Chuang A; Hanna F; Wilson E; Kwok C; Yan C; Gray Z; Mathew R; Falloon P; Dennis A; Pavlov T; Allen JC Semin Hematol; 2018 Oct; 55(4):223-234. PubMed ID: 30502851 [TBL] [Abstract][Full Text] [Related]
10. Iron status and analysis of efficacy and safety of ferric carboxymaltose treatment in patients with inflammatory bowel disease. Beigel F; Löhr B; Laubender RP; Tillack C; Schnitzler F; Breiteneicher S; Weidinger M; Göke B; Seiderer J; Ochsenkühn T; Brand S Digestion; 2012; 85(1):47-54. PubMed ID: 22179489 [TBL] [Abstract][Full Text] [Related]
11. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Evstatiev R; Marteau P; Iqbal T; Khalif IL; Stein J; Bokemeyer B; Chopey IV; Gutzwiller FS; Riopel L; Gasche C; Gastroenterology; 2011 Sep; 141(3):846-853.e1-2. PubMed ID: 21699794 [TBL] [Abstract][Full Text] [Related]
12. Ferric carboxymaltose vs. oral iron in the treatment of pregnant women with iron deficiency anemia: an international, open-label, randomized controlled trial (FER-ASAP). Breymann C; Milman N; Mezzacasa A; Bernard R; Dudenhausen J; J Perinat Med; 2017 May; 45(4):443-453. PubMed ID: 27278921 [TBL] [Abstract][Full Text] [Related]
13. TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose. Schatz U; Illigens BM; Siepmann T; Arneth B; Siegert G; Siegels D; Heigl F; Hettich R; Ramlow W; Prophet H; Bornstein SR; Julius U Atheroscler Suppl; 2015 May; 18():199-208. PubMed ID: 25936327 [TBL] [Abstract][Full Text] [Related]
14. A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia. Onken JE; Bregman DB; Harrington RA; Morris D; Acs P; Akright B; Barish C; Bhaskar BS; Smith-Nguyen GN; Butcher A; Koch TA; Goodnough LT Transfusion; 2014 Feb; 54(2):306-15. PubMed ID: 23772856 [TBL] [Abstract][Full Text] [Related]
15. Switching patients with non-dialysis chronic kidney disease from oral iron to intravenous ferric carboxymaltose: effects on erythropoiesis-stimulating agent requirements, costs, hemoglobin and iron status. Toblli JE; Di Gennaro F PLoS One; 2015; 10(4):e0125528. PubMed ID: 25928811 [TBL] [Abstract][Full Text] [Related]
16. Effectiveness and safety of ferric carboxymaltose compared to iron sucrose in women with iron deficiency anemia: phase IV clinical trials. Naqash A; Ara R; Bader GN BMC Womens Health; 2018 Jan; 18(1):6. PubMed ID: 29304848 [TBL] [Abstract][Full Text] [Related]
17. Safety and Efficacy of Ferric Carboxymaltose in the Treatment of Iron Deficiency Anaemia in Patients with Inflammatory Bowel Disease, in Routine Daily Practice. Stein J; Aksan A; Klemm W; Nip K; Weber-Mangal S; Dignass A J Crohns Colitis; 2018 Jun; 12(7):826-834. PubMed ID: 29955835 [TBL] [Abstract][Full Text] [Related]
18. A meta-analysis of ferric carboxymaltose versus other intravenous iron preparations for the management of iron deficiency anemia during pregnancy. Gupte S; Mukhopadhyay A; Puri M; Gopinath PM; Wani R; Sharma JB; Swami OC Rev Bras Ginecol Obstet; 2024; 46():. PubMed ID: 38765534 [TBL] [Abstract][Full Text] [Related]
19. Comparison of Iron Dosing Strategies in Patients Undergoing Long-Term Hemodialysis: A Randomized Controlled Trial. Bielesz B; Lorenz M; Monteforte R; Prikoszovich T; Gabriel M; Wolzt M; Gleiss A; Hörl WH; Sunder-Plassmann G Clin J Am Soc Nephrol; 2021 Oct; 16(10):1512-1521. PubMed ID: 34470831 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of intravenous ferric carboxymaltose compared with oral iron for the treatment of iron deficiency anaemia in women after childbirth in Tanzania: a parallel-group, open-label, randomised controlled phase 3 trial. Vanobberghen F; Lweno O; Kuemmerle A; Mwebi KD; Asilia P; Issa A; Simon B; Mswata S; Schmidlin S; Glass TR; Abdulla S; Daubenberger C; Tanner M; Meyer-Monard S Lancet Glob Health; 2021 Feb; 9(2):e189-e198. PubMed ID: 33245866 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]